Press release BoxID: 402782 (SynCardia Systems Inc)
  • SynCardia Systems Inc
  • 1992 East Silverlake Rd
  • AZ 85713 Tucson
  • Contact person
  • Don Isaacs
  • +1 (520) 955-0660

1st Hospital in UK Begins Certification to Implant SynCardia's Total Artificial Heart

Papworth Hospital in Cambridge is UK's Main Heart & Lung Transplant Center

(PresseBox) (Tucson, ) On Feb. 7, the surgical team from Papworth Hospital in Cambridge, United Kingdom, led by Dr. Steven Tsui, Consultant Surgeon & Director of Transplantation, will complete the first of four phases of certification to implant the SynCardia temporary Total Artificial Heart Papworth is the 66th hospital in the world and the first hospital in the UK to begin certification for the Total Artificial Heart.

“We are very excited to have Papworth join our program,” said SynCardia President Michael Garippa. “There are thousands of people suffering from biventricular failure in the UK who are out of options if a donor heart isn’t immediately available. For these patients, the Total Artificial Heart will be available for the very first time as a life-saving bridge to transplant.”

Papworth Hospital is the UK’s largest specialist cardiothoracic hospital and the country’s main heart and lung transplant center. Papworth is credited with performing the UK’s first successful heart transplant in 1979. Currently, the median waiting time for an adult donor heart at Papworth is 183 days, with the hospital performing 23 heart transplants in 2010.

According to the British Heart Foundation, approximately 700,000 people are living with heart failure in the UK. More than one in three of all deaths in the UK are caused by cardiovascular disease, which accounts for around 200,000 deaths each year. Overall, heart failure accounts for just over £625 million in total direct medical costs in the UK each year.

SynCardia Systems Inc

SynCardia Systems, the Tucson-based manufacturer of the world's only FDA, Health Canada and CE approved Total Artificial Heart: the SynCardia temporary Total Artificial Heart. There have been more than 900 implants of the Total Artificial Heart, accounting for more than 210 patient years of life on the device.

Originally used as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for people dying from end-stage biventricular failure. The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.